FDA Approves Abbott Xience DES For Short Dual-Antiplatelet Course

The agency approved the Xience stents as suitable for patients at high bleeding-risk who can only stay on antiplatelet therapy for four weeks. Abbott also announced that it has received FDA approval and European CE mark approval for its Xience Skypoint stent.